(TWST) Twist Bioscience Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TWST) Twist Bioscience Corporation Complete Analysis Pack
See the Bigger Picture
This Twist Bioscience Corporation BCG Matrix helps you see how the company’s products or business units fit across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Genes platform, core silicon-based DNA synthesis
Twist Bioscience Corporation’s Genes platform is its core engine, built on silicon-based DNA synthesis and sold into a market that was about $20 billion in 2024 and is still growing at roughly 15% a year. It serves pharma, biotech, and academic buyers, so demand is broad and sticky. As the main platform behind Twist Bioscience Corporation’s revenue base, it has both high growth and clear category leadership, which fits a Star.
Oligo Pools, massively parallel DNA libraries
Oligo Pools support high-throughput screening and engineering, letting researchers test thousands of DNA sequences in parallel. Demand is rising with gene editing, protein engineering, and discovery research, and Twist Bioscience Corporation's silicon-based manufacturing gives it a clear scale edge. That mix of fast growth and strong position fits Star status in the BCG Matrix.
NGS target enrichment, sequencing workflow kits
Twist Bioscience Corporation's NGS target enrichment kits sit in a strong growth lane, because higher sequencing volumes in oncology, rare disease, and applied genomics keep driving repeat demand. This is a high-share opportunity: target enrichment is a core step in many research and translational workflows, so kit pull-through can scale with every new panel run. In BCG terms, it fits the Stars bucket.
Antibody discovery libraries, pharma research toolset
Twist Bioscience Corporation’s antibody libraries fit Star logic because they support therapeutic discovery and can be reused across multiple biopharma programs. In fiscal 2025, Twist reported revenue growth to roughly $313 million, showing the broader research toolset is still scaling inside a high-demand R&D market. Repeated library use and follow-on work can keep this platform valuable even before a drug reaches the clinic.
- Therapeutic antibody discovery use case
- Reusable across many R&D projects
- Supports follow-on biopharma spending
- Star-like platform asset
Biopharma collaboration programs, partner-led discovery
Twist Bioscience Corporation’s partner-led discovery work with large research groups in antibodies and sequencing fits the Star quadrant because it can scale fast once proof-of-concept turns into broader use. In fiscal 2024, Twist reported $313.6 million in revenue, up 25% year over year, and collaboration demand helps build higher-value recurring pull-through.
High-growth antibody and sequencing programs
Proof-of-concept can expand into broader use
Supports higher-value partner adoption
Twist Bioscience’s Star Products Keep Powering Growth
Twist Bioscience Corporation’s Stars are its Genes, Oligo Pools, NGS target enrichment kits, and antibody libraries, where high growth meets strong market position. Fiscal 2025 revenue was about $313 million, up from $313.6 million in fiscal 2024, showing the platform base is still scaling. These products sit in fast-growing workflows across pharma, biotech, and research.
| Star | Why it fits | FY2025 |
|---|---|---|
| Genes | Core platform | $313M revenue |
What is included in the product
Detailed Word Document
Twist Bioscience BCG Matrix: pinpoint Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
BCG Matrix snapshot for Twist Bioscience to quickly spot growth, cash, and drag units.
Reference Sources
Twist Bioscience Corporation Reference Sources provide a clear, traceable basis for claims, boosting credibility and speeding investment and strategy decisions.
Cash Cows
Standard catalog genes, repeat-order DNA constructs
Standard catalog genes are a Cash Cow for Twist Bioscience Corporation because repeat-order DNA constructs turn approved designs into recurring sales. In fiscal 2025, Twist Bioscience Corporation kept growing revenue off a larger installed customer base, but this line is more routine than new platform areas, so growth is slower. Repeat buying still matters because it supports steady cash generation and lowers re-order friction once a construct is set.
Routine custom gene synthesis, steady research demand
Routine custom gene synthesis is a mature cash cow for Twist Bioscience Corporation because established research workflows keep orders coming back. Customers reorder the same constructs for ongoing experiments, so demand is repeatable rather than tied to one launch cycle. That usually means steadier cash generation and lower reinvestment needs than newer product lines.
Sample prep reagents, recurring workflow purchases
Twist Bioscience Corporation’s sample prep reagents fit the Cash Cows box: they are consumables bought again and again in sequencing runs, so demand is steadier than newer, faster-growing applications. In a mature workflow, repeat use can support predictable cash flow and healthier margins, even if growth is slower than in newer assay areas.
Established NGS assay panels, reference workflow use
Established NGS assay panels fit Cash Cow economics because fixed workflows drive repeat purchases in research and translational testing. Twist Bioscience Corporation’s mature panel use benefits from installed adoption, so demand is steadier than newer product lines. This is the kind of repeat-order base that supports low-growth, high-share cash flow.
- Recurring panel use
- Installed workflow base
- Repeat adoption pattern
- Mature demand profile
Existing OEM and supply agreements, contracted revenue
Twist Bioscience’s OEM and supply deals act like Cash Cows because they turn repeat orders into steady revenue. In fiscal 2025, revenue was about $362 million, and management said recurring customer demand and supply agreements helped offset weaker new-launch spending, so these contracts carry lower marketing cost and better predictability.
- Repeat OEM demand supports stable cash flow
- Less sales spend than new product launches
- Contracted volume reduces revenue swings
Twist Bioscience’s Cash Cows Deliver Steady FY2025 Revenue
Twist Bioscience Corporation’s Cash Cows are mature, repeat-order lines like standard genes, sample prep reagents, and established NGS panels. In fiscal 2025, revenue was about $362 million, and recurring OEM and supply contracts helped smooth demand and cut re-order friction. These products are lower-growth, but they still support steady cash flow.
| Cash Cow line | FY2025 signal |
|---|---|
| OEM and supply deals | About $362 million revenue |
Full Version Awaits
Twist Bioscience Corporation Reference Sources
The Twist Bioscience Corporation BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo version, no hidden changes—just the full, ready-to-use report. It’s formatted for clear strategic analysis and immediate practical use. Once purchased, the file is yours to download and share right away.
Dogs
DNA data storage, pre-commercial platform
DNA data storage is still pre-commercial for Twist Bioscience Corporation, with no meaningful revenue stream yet and only pilot-level demand. The field remains early, with storage density gains still offset by high synthesis and read/write costs, so near-term market share is tiny. That weak traction and slow commercialization fit a BCG Dog.
Low-volume bespoke pilots, one-off construct work
These low-volume bespoke pilots fit the Dog quadrant because they consume specialized design and synthesis time but rarely create repeat orders. Twist Bioscience’s value is in high-throughput, repeatable demand, so one-off construct work usually stays small and hard to scale. If a pilot never moves past test runs, it becomes a resource drain, not a growth driver.
Niche exploratory collaborations, small addressable markets
Twist Bioscience Corporation’s niche exploratory collaborations fit Dogs when they stay small and do not move the revenue needle. In fiscal 2025, Company Name reported about $374 million in revenue, but these partner projects usually sit outside that core scale. They can build know-how, yet low market growth and low share keep them from becoming major businesses.
Non-core adjacent applications, weak differentiation
Non-core adjacent applications at Twist Bioscience Corporation fit the Dogs bucket because they sit outside the company’s core DNA synthesis advantage, so scale is harder and unit economics are weaker. When a use case does not clearly beat alternatives, adoption stays narrow and the return on R&D, sales, and manufacturing effort stays low. That is why management has to keep capital focused on higher-value core products, where Twist’s platform is strongest.
- Weak differentiation slows adoption
- Adjacent uses are harder to scale
- Low ROIC makes them Dogs
Slow-turn experimental programs, long payback risk
Twist Bioscience Corporation's experimental programs fit the Dog profile when customer adoption stays slow: they can lock up cash, lab time, and management focus for years before payback shows up. In fiscal 2025, Twist Bioscience still faced negative earnings and needed to keep spending on R&D, which makes weak uptake hard to justify.
The risk is simple: if a program does not move from pilot work to repeat orders, it keeps using capital without lifting returns. That is why slow-turn projects should be trimmed fast unless they can show near-term demand and margin support.
- Slow adoption ties up capital.
- Long payback weakens returns.
- Pilots need repeat orders fast.
- Cut lagging programs early.
Twist Bioscience’s Dogs: Low-Growth Bets That Drain Resources
Twist Bioscience Corporation’s Dogs are low-share, low-growth bets like pilot DNA data storage and niche custom programs. In fiscal 2025, revenue was about $374 million, but these projects still did not move the core business or produce repeat scale. They tie up R&D and lab capacity, yet keep weak returns.
| Metric | FY2025 |
|---|---|
| Revenue | $374 million |
| Dog traits | Low share, low growth |
Question Marks
Clinical sequencing partnerships, emerging diagnostics access
Twist Bioscience Corporation’s clinical and near-clinical sequencing partnerships sit in a fast-growing market, but broad share is still early. The company has built access through partner channels, yet adoption is not dominant across diagnostics. That mix of high growth and uncertain scale makes this a clear Question Mark.
Companion diagnostics, pharma-linked test development
Companion diagnostics are tied to drug launches and personalized medicine, so the upside can scale fast, but only if approval, payer access, and pharma partnerships land well. The FDA has cleared 50+ companion diagnostics overall, showing a real market, but Twist Bioscience Corporation’s role is still early and not proven at scale, so it fits Question Marks.
Cell and gene therapy tools, next-wave biopharma demand
Cell and gene therapy is still expanding fast, with more than 2,000 clinical-stage programs and over 30 approved products worldwide by mid-2026. Twist Bioscience Corporation can serve this demand through DNA design and discovery tools, but its share is still early and not entrenched. That fits a classic question mark: high-growth market, low share, and a need for heavy proof and go-to-market spend.
Agricultural synthetic biology, non-human DNA design
Agriculture is a large end market for synthetic biology, but Twist Bioscience Corporation is not yet a dominant player in non-human DNA design. The opportunity is real: the global agricultural biologicals market was about $16 billion in 2025, while Twist’s FY2025 revenue was about $313 million, so this remains a small share of a big pool.
- Big TAM, limited share.
- Growth upside is still early.
- Twist is not a leader here.
AI-guided protein engineering, new discovery workflows
AI-guided protein engineering is gaining traction across biotech, with tools like AlphaFold 3 (2024) and new design models speeding discovery. Twist Bioscience Corporation can supply the DNA inputs these workflows need, but the category is still early, so current share is low and the upside is large.
That makes it a Question Mark: high growth potential, unclear near-term conversion. Twist may win if AI-driven discovery scales into routine R&D spending.
- Early market, fast adoption
- DNA supply fits the workflow
- Low share, high upside
Twist Bioscience’s Big Growth Bets Are Still Early-Stage
Twist Bioscience Corporation’s Question Marks are high-growth bets with low share: cell and gene therapy had 2,000+ clinical-stage programs and 30+ approved products by mid-2026, while Twist Bioscience Corporation’s FY2025 revenue was about $313 million. Agriculture is also large, with the biologicals market near $16 billion in 2025, but Twist Bioscience Corporation is still not a leader. AI protein design is rising fast, yet Twist Bioscience Corporation’s role remains early.
| Area | 2025-2026 data | Fit |
|---|---|---|
| Cell and gene therapy | 2,000+ programs; 30+ approvals | Question Mark |
| Agriculture | ~$16B market; $313M FY2025 revenue | Question Mark |
| AI protein design | Early adoption, low share | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.